Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Latanoprost
Drug ID BADD_D01251
Description Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment.[A184493] It has been found to be well-tolerated and its use does not normally result in systemic adverse effects like other drugs used to treat elevated intraocular pressure, such as [Timolol]. Another benefit latanoprost is that it can be administered once a day.[A184490]
Indications and Usage For the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Marketing Status Prescription; Discontinued
ATC Code S01EE01
DrugBank ID DB00654
KEGG ID D00356
MeSH ID D000077338
PubChem ID 5311221
TTD Drug ID D0C6NM
NDC Product Code 90027-006; 68071-2376; 59762-0333; 47335-317; 24208-463; 63190-0710; 65326-004; 45542-1156; 0009-5172; 51927-4864; 42385-039; 55545-0462; 71684-0547; 45542-1159; 68071-4893; 12079-0475; 64980-516; 50090-1920; 61314-547; 51927-0091; 68245-0002; 71205-154; 65035-128; 51552-1385; 17478-625; 46144-156; 65862-872; 40016-001; 71052-041; 61919-112; 65727-026; 61556-050; 65427-007; 81997-001; 68071-4650; 51927-0090; 24002-0018; 54893-0010; 10695-048; 0013-8303; 82231-111; 68071-4612; 70069-421
Synonyms Latanoprost | PhXA34 | PHXA41 | Xalatan
Chemical Information
Molecular Formula C26H40O5
CAS Registry Number 130209-82-4
SMILES CC(C)OC(=O)CCCC=CCC1C(CC(C1CCC(CCC2=CC=CC=C2)O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Bradycardia02.03.02.0020.001013%Not Available
Bronchitis22.07.01.001; 11.01.09.0010.000338%
Bronchospasm22.03.01.004; 10.01.03.0120.000338%
Burning sensation17.02.06.001; 08.01.09.0290.000901%Not Available
C-reactive protein increased13.09.01.0070.000225%Not Available
Cardiac failure02.05.01.001--
Cardiovascular disorder24.03.02.009; 02.01.01.0010.000059%Not Available
Cataract06.06.01.0010.006866%
Cellulitis23.09.01.001; 11.02.01.001--Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.000338%Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.000450%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.011--Not Available
Chills15.05.03.016; 08.01.09.001--
Choroidal detachment06.09.01.003; 12.01.04.0060.000450%Not Available
Coma17.02.09.001--Not Available
Compression fracture15.08.02.004; 12.04.02.0080.000225%Not Available
Confusional state19.13.01.001; 17.02.03.005--
Conjunctival haemorrhage24.07.05.001; 06.07.01.0010.001126%Not Available
Conjunctivitis11.01.06.012; 06.04.01.0020.000563%
Conjunctivitis allergic10.01.04.002; 06.04.01.0030.000563%Not Available
Corneal epithelium defect06.06.03.0120.000788%Not Available
Corneal erosion06.06.03.003--Not Available
Corneal oedema06.04.02.0010.000563%Not Available
Corneal opacity06.06.03.0050.000675%Not Available
Corneal scar12.01.04.015; 06.06.03.0150.000450%Not Available
Cough22.02.03.0010.001801%
Crohn's disease10.02.01.005; 07.08.01.0150.000225%Not Available
Death08.04.01.001--
Dehydration14.05.05.001--
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 10 Pages